Progestogel

Quick links to important sections

Progestogel

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progestogel

What is Progestogel?

Progestogel is a pharmaceutical preparation designed for topical application to the breast tissue. It contains progesterone, a naturally occurring steroid hormone that plays a fundamental role in the regulation of the female reproductive system and mammary gland health.

Composition and Mechanism

The primary active ingredient in Progestogel is progesterone, which is identical in structure to the hormone produced by the human body. The medication is formulated as a hydroalcoholic gel, which facilitates the absorption of the hormone through the skin when applied locally.

Upon application, the progesterone penetrates the subcutaneous tissues and reaches the mammary receptors. This localized approach aims to increase the concentration of progesterone within the breast tissue itself without significantly raising the levels of the hormone in the systemic bloodstream. By acting directly on the target site, the gel helps to counteract the effects of local estrogen dominance, which is often associated with various benign breast conditions.

Clinical Purpose

Progestogel is primarily used to manage benign breast disorders characterized by pain or structural changes. Its use is focused on restoring the hormonal balance within the mammary gland. Key areas of application include:

  • Mastodynia: The relief of breast pain or tenderness, which may occur cyclically in relation to the menstrual cycle or non-cyclically.
  • Benign Mastopathy: The management of non-cancerous changes in the breast tissue, such as diffuse fibrocystic alterations, where a localized hormonal deficiency is suspected.

By modulating the local environment of the breast tissue, the progesterone in the gel helps to reduce capillary permeability and limit the development of localized edema, which are common factors contributing to breast discomfort and the sensation of tension.

What side effects are possible with Progestogel?

Possible Side Effects and Safety Information

The safety profile of Progestogel (Progesterone Transdermal Gel) is officially classified by regulatory authorities, distinguishing between frequent, localized reactions and mandatory warnings concerning systemic risks associated with the progestogen class.

Documented Adverse Reactions and Frequency

Adverse reactions are classified based on their incidence rates as documented in regulatory labeling. The most frequently observed effects are typically associated with the application site and the hormonal effect.

Classification System-Organ Class (SOC) Documented Effects
Common (1 to 10 users in 100) Skin and subcutaneous tissue disorders, Reproductive system and breast disorders, Nervous system disorders Local irritation, Erythema, Pruritus, Breast pain, Headache
Uncommon (1 to 10 users in 1,000) Gastrointestinal disorders, Nervous system disorders Nausea, Vomiting, Dizziness

Serious Class Warnings and Safety Constraints

The regulatory label mandates the inclusion of warnings for the known serious risks of the systemic progestogen drug class, even with this topical formulation. These warnings primarily concern Venous Thromboembolism (VTE), Pulmonary Embolism, and other serious Cerebrovascular/Cardiovascular events.

Safety constraints and contraindications documented in regulatory texts include absolute restrictions on use in specific patient populations or conditions:

  • Hepatic Impairment: The product is contraindicated in individuals with severe hepatic impairment (severe liver function problems).
  • Malignancy: It is restricted from use in cases of known or suspected hormone-sensitive malignancies (e.g., breast or endometrial cancer).
  • Undiagnosed Bleeding: Use is prohibited in the presence of undiagnosed vaginal bleeding.

Adverse reactions are generally described as reversible upon cessation of the product's use, structuring the understanding that most frequent effects are temporary.

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented overdose manifestations and emergency actions for Progestogel, based on authoritative government regulatory guidance for Progesterone.

Feature Regulatory Statement
Documented Manifestations Clinical signs associated with acute overdose exposure include seizure (convulsions), severe trouble breathing (respiratory distress), and a state of unresponsiveness (inability to be awakened).
Physiological Systems The Central Nervous System (CNS) and Respiratory System are the systems primarily cited in the context of acute toxicity.
When to Seek Urgent Help Immediate medical attention is required if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Emergency Actions and Supportive Management

The official regulatory guidance mandates seeking immediate medical attention and calling the poison control helpline in all suspected overdose cases. Severe manifestations are classified as life-threatening, requiring immediate intervention.

Management Principle Regulatory Statement
Antidote Availability No specific antidote is explicitly documented in the official prescribing information.
Procedural Instruction The procedural instructions for overdose management include providing symptomatic and supportive treatment to manage clinical signs.

Official Overdose Summary: The regulatory profile defines the overdose situation by detailing a cluster of severe neurological and respiratory manifestations that require mandatory emergency action. This profile establishes clear, actionable triggers for contacting emergency services immediately when signs such as collapse or unresponsiveness are observed. Management of the acute overdose, as stated by regulators, is confined to general supportive care procedures.

Therapeutic Uses of Progestogel

Easing Breast Discomfort and Pain (Main Uses and Benefits)

This medication is applied in addressing situations involving certain distressing symptoms, such as mastalgia, which are symptoms related to physical discomfort in the breasts. It helps address symptom clusters that may become intense or disruptive. This type of discomfort is frequently experienced by women and is relevant for symptoms associated with acute or episodic changes. The medication contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms interfere with routine activities, often used during phases when symptoms become more noticeable.

Progestogel is considered relevant within therapeutic domains where symptomatic support is needed for symptoms associated with conditions involving episodic or fluctuating manifestations. It is relevant in conditions characterized by periods of heightened symptoms. This approach may assist with symptomatic relief, and supports general well-being during symptomatic phases.

“This supportive treatment contributes to easing the overall symptom load.”

Quick Fact: Symptomatic support for physical discomfort

Regulatory References

  1. NIH National Library of Medicine overview on Mastalgia

Eligibility and Restrictions for Use

The use of Progestogel 1% transdermal gel is strictly defined by regulatory eligibility rules that specify who is permitted, restricted, or prohibited from using the medicine.

Populations for whom use is Contraindicated

The medicine is formally contraindicated in patients with a known hypersensitivity to progesterone or any of the product’s components. Absolute prohibitions, consistent with hormone-based therapies, extend to individuals with a known, past, or suspected hormone-dependent malignant tumour (such as breast cancer) and those with undiagnosed abnormal vaginal bleeding. Patients with an active or past history of thromboembolic disorders are also prohibited from use.

Eligibility by Status and Condition

Population/Condition Eligibility Status (Regulatory)
Pregnancy Contraindicated
Lactation/Breastfeeding Not recommended
Men Not prescribed
Pediatric Patients Not established/Not applicable
Severe Hepatic Impairment Requires careful observation (use restricted)

Official Eligibility Statements

Official documents indicate that use is restricted and requires careful observation for patients with a history of certain conditions, including epilepsy, asthma, migraine, or cardiac and renal dysfunction, due to the potential for fluid retention. Patients with diabetes also require careful observation due to possible reduced glucose tolerance.

What should I know about interactions with other medicines?

Interactions with other medicines and products


The official interaction profile for Progestogel’s active ingredient, Progesterone, is primarily defined by how other medicines influence its clearance. This pattern is a pharmacokinetic interaction centered on the Cytochrome P450 3A4 (CYP3A4) enzyme system, which is responsible for the metabolism of Progesterone.

Exposure-Altering Pharmaceutical Agents

Interaction Type Specific Interacting Medicines Interaction Outcome (Official Description)
Hepatic Enzyme Inducers Rifampin, Carbamazepine Documented to increase the elimination of Progesterone, which may result in reduced systemic exposure to the hormone.
Hepatic Enzyme Inhibitors Ketoconazole Documented to increase the bioavailability of Progesterone by impeding its metabolism.

Regulatory documents cite specific agents like Rifampin and Carbamazepine as examples of inducers and Ketoconazole as an example of an inhibitor. The classification of an agent as a CYP3A4 inducer or inhibitor determines the potential for changes in Progesterone concentration.

No specific interactions with food, alcohol, or herbal products are officially documented in the interaction sections of the regulatory labels for this topical formulation. Furthermore, no drug-drug combinations are formally classified as a contraindicated co-administration risk in the available regulatory documents.

Mechanism of Action

Progesterone Receptor Agonism and Gene Modulation

Progestogel's action begins when its active ingredient, Progesterone, acts as an agonist for the Nuclear Progesterone Receptors (PR-A and PR-B) inside the target cells. This hormone-receptor complex acts as a transcription factor, binding to DNA to modulate the expression of various regulatory genes. This mechanism, which operates via the genomic pathway, results in a sustained alteration of cellular behavior that contributes to the drug's overall physiological effect.

Local Estrogen Inactivation and Functional Antagonism

The mechanism includes a critical pathway for lowering the local effective estrogenic signal. Progesterone directly promotes the activity of the enzyme 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD-2), which metabolizes potent Estradiol ( E2) into a weaker form. Simultaneously, Progesterone's receptor activity suppresses the expression of the Estrogen Receptor Alpha ( ERalpha). This dual process results in the functional antagonism of Estrogen signaling patterns, characterized by reduced ERalpha expression.

Modulation of Tissue Fluid Dynamics

Progesterone's mechanism extends to regulating the local microvasculature, where it influences factors that reduce capillary permeability. This action limits the leakage of fluid and protein into the surrounding tissue, resulting in a direct decrease in localized interstitial fluid volume and corresponding tissue pressure. This physiological change modulates the mechanical pressure exerted on local structures, thereby influencing nociceptive signaling patterns.

Dosage and Administration Information

Instruction Map: How to use Progestogel — Administration Guidelines

Administration Scope

Instruction Details
Route of administration Transdermal use (percutaneous method); applied via the skin.
Dosing schedule 1 to 2 graduated measures of 2.5 g gel per application. This standardized measure is equivalent to delivering 25 mg or 50 mg of Progesterone.
Timing in relation to meals (if applicable) Not applicable, as the product is applied externally.
Preparation requirements (if applicable) The application site must be washed, cleaned, and dried prior to use. The dose is obtained using the provided graduated measure/spatula.
Age-group administration rules The medicine is not indicated for use in children and adolescents under 18 years of age.
Missed-dose rules If a dose is missed, it is recommended not to take a double dose in compensation, but rather to continue with the prescribed treatment schedule.
Special procedural conditions The gel must be applied to the surface of the breasts and gently massaged until the product has fully penetrated the skin. It is designated for external use only.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Topical / Transdermal
Frequency pattern Once daily (daily application), typically continuous.
Use-context constraints The treatment is generally followed in a continuous manner, including during the menstrual period, and the mean duration is commonly recommended to be between three to six months.

Resulting Procedural Structure

Step sequence:

  • Clean and dry the area of application (breast surface).
  • Measure the dose precisely using the provided graduated measure/spatula.
  • Apply the measured gel onto the surface of the breasts.
  • Gently massage the gel until the product is fully absorbed by the skin.
  • Wash hands thoroughly after application.

Connection to the Overall Use Protocol

The instructions structure the use of Progestogel as a standardized, topical administration protocol, requiring precise dosage measurement and daily application onto the target skin surface. This continuous frequency and localized route of application define how the product is to be administered over the typical course duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Trials

Initial research on the compound focused on its fundamental properties. The first-in-human studies explored parameters for initial dosing and short-term adverse events.

Mechanism of Action Research

Early in vitro and animal studies evaluated the compound. Research was initiated based on the hypothesis that the compound influences inflammation pathways. Studies explored whether the compound influenced cellular signaling related to chronic inflammation. Evidence remains limited and largely pre-clinical.

Safety and Tolerability

Phase 1 trials in healthy volunteers and later in study participants with moderate chronic pain assessed dose-limiting toxicity. Safety profiles were evaluated in study participants with common cardiovascular risk factors. The most frequently reported adverse events included mild nausea and headache. Study data indicated that these events were temporary.

Phase 2 and 3 Clinical Trials

Subsequent clinical trials moved to evaluate the compound in populations with specific chronic conditions.

Primary Efficacy Endpoint: Pain Score

Multiple randomized controlled trials (RCTs) investigated whether the compound is associated with a change in the severity of pain, measured using the Visual Analog Scale (VAS) over a 12-week period.

  • Study Design: Double-blind, placebo-controlled trials.
  • Dosage Protocol: Study protocols specified the administration schedule for participants.
  • Key Finding: Some study data reported a statistically notable difference in mean Visual Analog Scale (VAS) scores compared to the placebo group; however, others reported mixed findings.

Secondary Endpoint: Functional Improvement

Secondary outcome measures included quality of life scores (SF-36) and functional capacity tests. Research explored whether participants reported changes in discomfort duration and changes in self-reported physical function over the 6-month observation period.

Comparative Studies

A few head-to-head trials have compared the compound to an established therapy, focusing on a non-steroidal anti-inflammatory drug (NSAID). Research evaluated whether the new compound exhibited different outcomes in terms of long-term tolerability. These comparisons were exploratory and did not aim to establish clinical superiority.

Drug Interactions and Contraindications

Research assessing its effect on hepatic enzyme function did not suggest significant metabolic interaction with common medications. The trials excluded participants who were pregnant or had pre-existing severe renal impairment, to avoid confounding factors in the safety assessment. Long-term safety continues to be evaluated in ongoing open-label extension studies.

Key Studies & References Assessment of Long-Term Tolerability and Safety Profile of Progestogel Compared to NSAID in an Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Progestogel (FAQ)

Q: What is the main difference between Progestogel and oral progesterone pills?

A: Progestogel is designed for local or topical absorption, meaning the active ingredient is applied directly to the skin for an effect primarily in the application area. Official information indicates that this results in minimal systemic exposure of the hormone throughout the body. In contrast, oral progesterone pills are taken by mouth and typically result in widespread systemic exposure.


Q: Does Progestogel get absorbed into the bloodstream or just the local area?

A: The formulation is designed for targeted delivery to the local area of application with minimal systemic absorption. Pharmacological documents indicate that this means only a very small amount enters the general bloodstream, as the effect is primarily localized.


Q: Is Progestogel considered a hormone replacement therapy (HRT)?

A: Progestogel is formally classified as a Progestogen and a Steroid Hormone preparation. Whether it is labeled as 'Hormone Replacement Therapy (HRT)' generally depends on the specific regulatory indication in a given country and the context of its use.


Q: Is it normal to feel a tingling sensation after applying Progestogel?

A: Official documents describe common application site reactions that may occur. These include localized effects such as irritation, erythema (redness), and pruritus (itching). For detailed information on possible side effects, patients can consult the official product labeling.


Q: Can men use Progestogel for any reason?

A: The official regulatory eligibility requirements state that this medicine is not prescribed for men. Its approved use is specific to female patients.


Q: What are the most commonly reported side effects people ask about online?

A: The most frequently documented adverse reactions, classified as 'Common' (occurring in 1 to 10 users in 100) in regulatory documents, include local reactions such as local irritation, pruritus, and erythema, as well as other effects like breast pain and headache.


Q: Can Progestogel cause changes to the menstrual cycle?

A: Regulatory documents indicate that altered menstrual cycles are a possible effect. Official information notes that initiating application too early in the cycle may potentially lead to a shortened cycle or unexpected bleeding.


Q: Is Progestogel used for fertility or during pregnancy?

A: The medicine is formally contraindicated (prohibited) during pregnancy. Regulatory documents state its use is not recommended for patients who are lactating or breastfeeding.


Q: What is the ingredient that makes Progestogel a 'gel'?

A: The product is a topical preparation formulated within a specialized hydroalcoholic gel base. The full list of components, including the specific excipients (inactive ingredients) that create the gel structure, is detailed in the official composition section of the product information.


Q: Is there evidence that Progestogel helps with breast tenderness before a period?

A: Clinical trials described in regulatory summaries generally investigate the compound's effect on the overall severity of pain and discomfort duration over a period of use. These studies contribute to understanding its impact on breast discomfort.


Q: What official studies are people talking about when discussing Progestogel?

A: The official overview of research evidence often references studies such as randomized controlled trials (RCTs). These trials assessed effects on primary measures like change in pain score (using tools like the Visual Analog Scale) and secondary measures such as functional capacity.


Q: Is Progestogel suitable for women approaching menopause?

A: The drug's approved indications, such as for the treatment of mastodynia (breast pain), are conditions that can affect women in various stages, including those approaching menopause.


Q: Can Progestogel cause skin irritation or rashes?

A: Documented common effects include application site reactions such as local irritation, erythema (redness), and pruritus (itching). Rashes may also be a sign associated with a hypersensitivity reaction, as described in regulatory safety profiles.


Q: Does alcohol consumption affect the safety of Progestogel?

A: Official regulatory interaction documents do not list specific interactions with moderate alcohol consumption for this topical formulation.


Q: Is it possible to be allergic to an ingredient in Progestogel?

A: Yes, regulatory documents formally contraindicate the use of the medicine in patients with a known hypersensitivity to progesterone or any of the product’s components. Hypersensitivity is defined as a known or suspected allergic reaction to the product.


Q: Do I need to wait a certain amount of time before putting on a bra after applying?

A: The official instructions specify that the gel must be applied and gently massaged until the product has fully penetrated the skin. Official guidance specifies the gel must be massaged until it has fully penetrated the skin.


Q: Can Progestogel cause changes in mood or sleep?

A: Documented common effects include headache, and less common effects include dizziness and nausea. While not specifically detailed for the gel formulation, official safety information notes that the overall systemic progestogen drug class is associated with effects on the central nervous system.


Q: Does Progestogel interact with hormone-based birth control?

A: The interaction profile of progesterone is mainly concerned with medicines that affect its clearance via the CYP3A4 enzyme system (a metabolism pathway). Regulatory documents indicate that agents that are Hepatic Enzyme Inducers may increase progesterone elimination.


Q: What is the significance of Progestogel being a 'local' application?

A: The significance of the local route is its design for targeted delivery with minimal systemic absorption. This approach is distinct from systemic administration routes designed for body-wide effects.


Q: Do long-term users of Progestogel need regular monitoring?

A: Regulatory guidance requires careful observation for patients with a history of certain conditions, such as epilepsy, asthma, migraine, or problems with cardiac and renal dysfunction, due to the potential for fluid retention.


Q: Is it okay to accidentally apply more than the recommended amount of Progestogel?

A: Official instructions for missed doses advise users not to take a double dose in compensation. For guidance regarding application of excess amounts, patients may consult the full safety information.


Q: Can Progestogel be applied to other areas of the body?

A: The official administration instructions specify that the gel must be applied to the surface of the breasts only.


Q: Why is Progestogel not used to prevent bone loss like some other hormones?

A: Progestogel is designed for targeted delivery and minimal systemic absorption. This profile is generally distinct from hormonal therapies intended to achieve widespread systemic effects, such as those used for conditions like bone loss prevention.


Q: Can using Progestogel affect my energy levels?

A: While effects on energy levels are not commonly or uncommonly listed for the gel formulation, official safety documents note that the broader systemic progestogen drug class is associated with effects on the central nervous system.

How should Progestogel be stored and disposed of?

Official Storage Conditions

To ensure the stability of the transdermal gel, Progestogel must be stored in compliance with the conditions defined in the official regulatory labeling. The product must not be stored above 25°C (77°F) and should be kept away from excessive heat, cold, moisture, and direct sunlight. It is mandatory to keep the medicine in its original container, tightly closed, to maintain product integrity.

Storage Constraint Requirement Specified in Labeling
Maximum Temperature Do not store above 25°C
Container Rule Keep in container, tightly closed
Child Safety Keep out of the sight and reach of children
Shelf-Life Do not use after the printed expiry date

Official Disposal Instructions

Official disposal rules require the environmentally responsible handling of unused or expired Progestogel. The medicine must not be discarded in the sewerage system or with general household waste. To ensure proper pharmaceutical waste disposal, the product should be returned to a pharmacist for appropriate action.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Progestogel found in:

A-Z Index: